David L. Veenstra, PharmD, PhD
Articles
October 14th 2021
Reimbursement for Genetic Variant Reinterpretation: Five Questions Payers Should Ask
David L. Veenstra, PharmD, PhD John W. Rowe, MD José A. Pagán, PhD H. Shelton Brown, PhD John E. Schneider, PhD Avni Gupta, BDS, MPH Sara M. Berger, MS, CGC Wendy K. Chung, MD, PhD Paul S. Appelbaum, MD
Periodic reinterpretation of genetic sequencing results presents a challenge for developing transparent and systematic coverage and reimbursement policies.
January 19th 2012
Systematic Review of Comparative Effectiveness Data for Oncology Orphan Drugs
Mindy M. Cheng, MS Scott D. Ramsey, MD, PhD Emily Beth Devine, PharmD, MBA, PhD Louis P. Garrison, PhD Brian W. Bresnahan, PhD David L. Veenstra, PharmD, PhD
This study critically assessed the published clinical and economic evidence supporting oncology orphan drugs marketed in the United States.
Latest Updated Articles
Published: August 18th 2025 | Updated: August 25th 2025
Conditional Economic Incentives Could Be Effective in Improving Adherence to Long-Acting PrEP in Transgender Adults
Published: August 19th 2025 | Updated: August 22nd 2025
Semaglutide Not Associated With Increased Risk of Eye Disorders
Published: June 6th 2025 | Updated: August 18th 2025
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
Published: June 27th 2025 | Updated: July 1st 2025
Report Reveals Mounting Burdens of Drug Shortages on US Health System
Published: February 20th 2025 | Updated: February 21st 2025
Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP
Published: January 16th 2025 | Updated: January 29th 2025
FDA Proposal Aims to Reduce Smoking Addiction and SCLC Cases
